Last checked at 25 Feb 2022 07:00
Kanabo Group Plc
("Kanabo" or the "Company")
Director/PDMR Dealing
Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company focussing on the development and distribution of cannabis-derived products for medical patients and wellness CBD consumers, announces Daniel Poulter, Non- Executive Director, has purchased 55,000 ordinary shares at a price of 7.4p.
Avihu Tamir, CEO, commented: "Since joining Kanabo in June 2021 Dan has become an invaluable member of the board. I welcome his most recent show of support by acquiring shares in the market. With the recent acquisition of the GP Service, and completion of an oversubscribed fundraise, Kanabo has approximately £6.4m and is well positioned to implement its growth strategy".
The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc | Via Vox Markets |
Avihu Tamir, CEO |
|
Peterhouse Capital Ltd (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
Eran Zucker / Lauren Riley |
|
Peterhouse Capital Ltd (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
Lucy Williams / Charles Goodfellow | |
Vox Markets (Investor Relations) | KanaboGroup@voxmarkets.co.uk |
Kat Perez | kperez@voxmarkets.co.uk |
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name Daniel Poulter
|
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
| ||||
a)
| Name
| Kanabo Group Plc | |||
b)
| LEI
| 213800XPJFSNWJIYKN52 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 2.5 pence each in Kanabo Group Plc | |||
|
| ||||
Identification code | GB00BYQCS703 | ||||
|
| ||||
b)
| Nature of the transaction
| Purchase of shares | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| 7.4p | 55,000 |
| |
|
|
|
|
| |
d)
| Aggregated information |
| |||
|
| ||||
- Aggregated volume | 55,000 | ||||
|
| ||||
- Price | £4,053 | ||||
|
| ||||
e)
| Date of the transaction
| 24/02/2022 | |||
f)
| Place of the transaction
| Standard List of the Main Market | |||
Following the share purchase, Mr Poulter's beneficial interests in the capital of the Company is 0.013%.
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.